Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 14;5(1):e250016.
doi: 10.1530/EO-25-0016. eCollection 2025 Jan.

Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndrome

Kalyan Mansukhbhai Shekhda  1 , Eleni Armeni  1 , Dalvinder Mandair  1 , Aspasia Manta  2 , George Parker  1 , Akanksha Sarma  1 , Aimee Hayes  1 , Martyn Caplin  1 , Christos Toumpanakis  1
Affiliations

Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndrome

Kalyan Mansukhbhai Shekhda et al. Endocr Oncol. .

Abstract

Objective: To evaluate clinical outcomes, safety and survival measures of octreotide infusion pump (OIP) therapy in patients with metastatic neuroendocrine tumors (NETs) and refractory hormonal syndrome.

Design: A retrospective analysis was conducted using data from patients treated with OIP therapy at a single center.

Methods: Data on demographics, disease characteristics, biochemical profiles and treatment outcomes were extracted from electronic patient records.

Results: Eighteen patients with NETs and debilitating symptoms refractory to maximum approved doses of somatostatin analogs (SSTAs) were included. The cohort comprised 18 patients (12 males (67%) and six females (33%)) with a median age of 64.5 years (IQR: 49.5-71). The most common tumor site was midgut (72.2%), followed by pancreas (22.2%). Refractory carcinoid syndrome was the primary indication for initiation of OIP therapy in 15 patients and VIPoma in three. Most tumors were WHO grade 1 or 2 (89%), and liver metastases were prevalent (94% of patients). At presentation, the median 24-h urinary 5-hydroxyindoleacetic acid (5-HIAA) level was 421.5 μmoL/24 h (n: 8). The mean starting OIP dose was 1,632 ± 522 μg/24 h, escalating to 2,166.7 ± 464 μg/24 h in 66.57% of patients. Symptomatic improvement was observed in 72% of patients, significantly reducing flushing and diarrhea. Patients who did not respond well to OIP therapy had more disease burden and had received more treatment lines before being started on OIP therapy.

Conclusion: OIP therapy is an effective treatment option for symptom control in patients with refractory NET-related hormonal syndrome. Randomized controlled trials are warranted to confirm these findings and assess long-term outcomes.

Keywords: carcinoid syndrome; neuroendocrine tumors; octreotide infusion pump; refractory hormonal syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the work reported.

Figures

Figure 1
Figure 1
Percentage of patients exhibiting symptoms with each treatment category. SC, subcutaneous; OIP, octreotide infusion pump.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Angelousi A, Koumarianou A, Chatzellis E, et al. . 2023. Resistance of neuroendocrine tumours to somatostatin analogs. Expert Rev Endocrinol Metabol 18 33–52. (10.1080/17446651.2023.2166488) - DOI - PubMed
    1. Baldelli R, Barnabei A, Rizza L, et al. . 2014. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol 5 7. (10.3389/fendo.2014.00007) - DOI - PMC - PubMed
    1. Bösch F, Bazhin AV, Heublein S, et al. . 2019. Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors. BMC Cancer 19 575. (10.1186/s12885-019-5794-y) - DOI - PMC - PubMed
    1. Broder MS 2015. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol 21 1945. (10.3748/wjg.v21.i6.1945) - DOI - PMC - PubMed
    1. Caplin ME, Pavel M, Ćwikła JB, et al. . 2014. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371 224–233. (10.1056/NEJMoa1316158) - DOI - PubMed

LinkOut - more resources